Research Roundup: June 17, 2025
- Lex Pelger
- Jun 17
- 2 min read
Best of cannabinoid science this week...
In people with obsessive-compulsive disorder, after 3 months of medical cannabis, there were substantial improvements in quality of life, general health, mood/depression, anxiety & sleep
Medicinal Cannabis Use Among People with Obsessive Compulsive Disorder: Changes in Quality of Life After Three Months
In people with multiple sclerosis, 1 month of CBD improved their gait & reduced their pain
A randomized trial on efficacy of purified cannabidiol on spasticity in multiple sclerosis patients with gait problems: first report in Iran
A CBD topical protected the skin from UVA damage
Novel CBD Cream Shows Promise in Protecting Skin from UV-A Damage in First-Ever In-Human Trial
For atopic dermatitis (eczema), a systematic review of 12 studies found improvements to hydration, itching & eczema scores
Therapeutic effectiveness and safety of cannabinoids in the treatment of atopic dermatitis: a systematic review
For CBD in skin conditions, they showed improved anti-inflammatory & wound healing effects as well as efficacy for acne, psoriasis & eczema
Nanoformulated cannabidiol for skin disorders: A GRADE-based systematic review of therapeutic evidence and efficacy
For psoriasis, a review of CBD topicals
THERAPEUTIC EFFECT OF CANNABIDIOL (CBD) IN PLAQUE PSORIASIS
For neuropathic pain, a systematic review of 22 studies found significant pain reduction in “multiple sclerosis, spinal cord injuries, diabetic neuropathy, postherpetic neuralgia, HIV-associated sensory neuropathy, peripheral neuropathic pain, complex regional pain syndrome, chronic radicular neuropathic pain, and peripheral neuropathy of the lower extremities”
Are Cannabis-Based Medicines a Useful Treatment for Neuropathic Pain? A Systematic Review
For CBD & cognition, a review of 36 studies looked at effects for Parkinson's disease, anxiety, psychosis & cognitive function in people with substance use disorders
Cannabidiol and cognition: a literature review of human randomized controlled trials
For Alzheimer's & Parkinson's, a review of the preclinical literature on the benefits of CBD & targeting the ECS (good charts)
Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson’s and Alzheimer’s Disease
For glaucoma, a review of cannabinoids to reduce intraocular pressure
Cannabinoids Modulations in Intraocular Pressure and Therapeutic Intervention for Glaucoma
In a mouse model of schizophrenia, CBD protected from the memory deficits, activation of the microglia (guardian immune cells of the brain) & decreased gamma neural oscillations via the CB2 & 5-HT1A serotonin receptor in the ventral hippocampus but not those receptors in the prelimbic medial prefrontal cortex
Cannabidiol reverses microglia activation and loss of parvalbumin interneurons and perineuronal nets in a mouse model of schizophrenia
In a rat model of methamphetamine use disorder, CBD reduced reward-seeking behavior via the D2 dopamine receptors in the hippocampus (memory center of the brain)
Cannabidiol mechanism of action on modulating extinction and reinstatement of methamphetamine-seeking behavior: Targeting D2-like dopamine receptors in the hippocampus
Comments